{"id":"layla-tablet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL635","moleculeType":"Small molecule","molecularWeight":"358.43"},"_fixedAt":"2026-03-30T14:25:38.383496","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This increase in serotonin levels helps to improve mood, reduce anxiety, and prevent the recurrence of depression. SSRIs like LAYLA tablet are commonly used to treat major depressive disorder, generalized anxiety disorder, and other conditions. They can take several weeks to start working and may have side effects such as nausea, dizziness, and insomnia.","oneSentence":"LAYLA tablet is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:40.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT02049606","phase":"PHASE4","title":"To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee","status":"COMPLETED","sponsor":"PMG Pharm Co., Ltd","startDate":"2014-02-24","conditions":"Osteoarthritis of the Knee","enrollment":134},{"nctId":"NCT01768468","phase":"PHASE4","title":"To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients","status":"COMPLETED","sponsor":"PMG Pharm Co., Ltd","startDate":"2012-10","conditions":"Osteoarthritis of the Knee","enrollment":124}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"2026 Jan","pmid":"41513203","title":"Leveraging complementary functions of hydroxypropyl methylcellulose and croscarmellose sodium to develop gastroretentive tablets via predictive regression-based modeling.","journal":"International journal of biological macromolecules"},{"date":"2024 Nov 15","pmid":"39560548","title":"Comparison of a fixed-dose combination of Celecoxib/PG201 [Layla®] versus co-administration of individual formulations in healthy participants: A randomized trial.","journal":"Medicine"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LAYLA 405.4mg"],"phase":"marketed","status":"active","brandName":"LAYLA tablet","genericName":"LAYLA tablet","companyName":"PMG Pharm Co., Ltd","companyId":"pmg-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LAYLA tablet is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain. Used for Major depressive disorder, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}